Abeona Therapeutics (ABEO) Return on Capital Employed (2011 - 2026)

Abeona Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.55% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 8734.0% year-over-year to 6.55%; the TTM figure through Mar 2026 stood at 6.55% (up 8734.0% YoY), while the FY2025 annual figure was 11.12%, up 10300.0% from the prior year.
• Return on Capital Employed was 6.55% for Q1 2026 at Abeona Therapeutics, down from 7.65% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 7.65% in Q4 2025 to a low of 290.43% in Q3 2022.
• Historically, Return on Capital Employed has averaged 95.73% across 5 years, with a median of 82.48% in 2023.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed slumped 23181 bps in 2022, then surged 19927 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 116.49% in 2022, then increased by 22 bps to 91.31% in 2023, then advanced by 28 bps to 65.4% in 2024, then soared by 112 bps to 7.65% in 2025, then retreated by 14 bps to 6.55% in 2026.
• The last three Return on Capital Employed figures came in at 6.55% (Q1 2026), 7.65% (Q4 2025), and 38.44% (Q3 2025), per Business Quant data.